- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA panel pegs price of Hetero Labs HIV drug Darunavir Ethanolate at Rs 190.44 per tablet
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) Committee has suggested the retail price of each film-coated tablet containing Darunavir Ethanolate, which is equivalent to Darunavir IP 800 mg plus Ritonavir IP 100 mg, at Rs. 190.44 per tablet excluding GST, manufactured by Hetero Labs Ltd. and marketed by Cipla Ltd.
This came after the Multidisciplinary Committee of Experts deliberated on the retail price fixation of the popular protease inhibitor Darunavir Ethanolate, which is used to treat HIV.
Darunavir Ethanolate is the ethanolate form of darunavir, which is a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor. Darunavir, in general, is used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection.
Darunavir specifically targets and binds to the active site of HIV-1 protease after oral administration, inhibiting dimerization and catalytic activity of HIV-1 protease.In HIV-infected cells, this suppresses the proteolytic cleavage of viral Gag and Gag-Pol polyproteins. This suppression results in the synthesis of immature, non-infectious viral proteins that are unable to form mature virions and prevents HIV replication.
Due to in vitro data confirming its capacity to battle SARS-CoV-2, the coronavirus responsible for COVID-19, darunavir is also being explored as a potential therapy for Covid 19.
Also Read: No benefit of Lopinavir–Ritonavir combo in severe COVID-19, says NEJM
After detailed deliberation, the committee recommended the retail price of each film-coated tablet containing Darunavir Ethanolate eq. to Darunavir IP 800 mg + Ritonavir IP 100 mg for M/s Hetero Labs Ltd. (manufacturer) and M/s Cipla Ltd. (marketer) at Rs. 190.44 per tablet excluding GST as detailed below:
Sl. No. | Company | Price To Retailer (PTR) as per Fom-V submitted by the company | PTR per tablet |
1 | Hetero Healthcare Ltd | Rs. 5109.29 per 30 tablet | Rs.170.30 |
2 | Emcure Pharmaceuticals Ltd | Rs. 4741.20 per 30 tablet | Rs. 158.04 |
Therefore, average PTR | Rs. 164.17 | ||
Add: 16% retailer margin | Rs. 26.27 | ||
Worked out the retail price per tablet | Rs. 190.44 |
Also Read: NPPA panel suggests price Of Ivabradine Hydrochloride tablet marketed by Lupin